Advances in Ophthalmology - Newsletter Archive
If you would like to be added to our newsletter mailing list or receive copies of other material you see at this site, please send an email message to email@example.com.
You will need to have Acrobat Reader installed on your computer to view the pdf version of these newsletters. If you don't already have Acrobat Reader, download Acrobat Reader here.
Fall 2012 - Kellogg Eye Center asks why some children do not receive proper care after failed vision screenings
A two-year grant from the W.K. Kellogg Foundation will allow our ophthalmologists and researchers, along with collaborators around Michigan, to tackle disparities in children's eye care that may result in delayed detection of eye disease or inadequate follow-up once
a problem has been identified.
Artist Ted Ramsay didn’t realize that darkness had crept into his paintings. Then, during a routine eye exam, he learned that he had the wet form of macular degeneration. After a course of injections, Professor Ramsay was able to return to his studio. Among his newest works are digital collages reflecting his perception of the disease and the treatment he received at the Kellogg Eye Center.
Collaboration and discovery were the watchwords of the day as Kellogg’s new building was dedicated. Keynote speaker, Gail Wilensky, Ph.D., U-M President Coleman, and others praised the vision that led to the unique design of the building, which encourages collaboration, and the promise that it brings to people who suffer from diabetic retinopathy and vision loss of all kinds.
Winter 2010 - A Doctor and Patient Take on Wegener’s Disease
After five eye surgeries and a lengthy hospital stay, Mary Ann Brandt regained both her vision and her health. She was found to have Wegener’s disease, an uncommon disorder that attacks tissue and vital organs. Ms. Brandt remained steadfast throughout the ordeal and today she credits the medical staff of the U-M Health System for her good fortune. She gives special thanks—and a unique gift—to retinal surgeon Dr. Stephen Saxe.
Spring 2009 - Kellogg Physician Saves Vision in Young Man with Diabetic Eye Disease
A 24-year-old young man suffered from a virulent form of diabetic eye disease that caused blindness in one eye and threatened the other. Over the course of several months retina specialist Dr. Mark Johnson treated the abnormal blood vessels with lasers and two surgeries. He restored the vision in this young man's threatened eye so that he is now able to read, drive, and work again.
Spring 2008 - Kellogg Faculty Invent Camera that "Sees" Disease before Symptoms Appear
When retinal cells undergo metabolic stress and begin to die, they become fluorescent. This fluorescence can be an early-warning system for diseases such as glaucoma and diabetic retinopathy, letting doctors know there are problems before the patient experiences any symptoms. This camera allows diseases to be treated early, thus saving sight in these patients.
Fall 2007 - Clinical Trial Begins for Retinitis Pigmentosa Patients
Kellogg is one of 14 centers across the country to test a possible treatment for retinitis pigmentosa. Dr. John Heckenlively leads the trial for Kellogg in which patients may have a sustained-release capsule implanted into one eye. The capsule releases a naturally occurring protein, ciliary neurotrophic factor, that is known to retard retinal degeneration.
Spring 2007 - Photoreceptor Cell Death is Often the Culprit in Vision Loss
After years of research Anand Swaroop's lab found that rod precursors held more promise in replacing photoreceptors than mature rods or stem cells. This dramatic breakthrough enabled light-sensing cells to be transplanted successfully into mice. The mice were then able to "see" light, as shown by pupillary responses.
Spring 2006 - New Technology Speeds Precise Diagnosis of Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a group of diseases that cause people to begin to lose vision at an early age. Until now, the specific type of RP was difficult to identify. However, Dr. Radha Ayyagari has developed a rapid genetic test that can distinguish one type from another.
Fall 2005 - Unraveling the Genetic Basis of AMD
Researchers around the world have independently confirmed that a single chromosomal variant appears to be a key factor for nearly half the patients suffering from AMD. Dr. Anand Swaroop led the Kellogg team that discovered the role of Complement Factor H; he calls it a “giant leap forward in our journey towards meaningful treatment.”
Spring 2005 - Why Healing Is Sometimes a Bad Thing
Among the most common treatments for glaucoma is surgery to open a channel that allows the excess fluid to drain. Dr. Sayoko Moroi notes that the body frequently closes this channel in an attempt to “heal” the drainage hole. She uses amniotic membranes to fool the body’s natural defense mechanisms.
Fall 2004 – Eyelid Cancers – Common but Curable
Once cancer cells grow deeper than the skin it becomes increasingly difficult to remove them all during surgery. Dr. Christine Nelson explains that the tissue behind the eye is particularly treacherous territory for isolating cancer cells. But if these cancers are managed early there is a high degree of success both for eliminating the cancer and retaining vision.
Summer 2004 - Vision Loss from “Wet” AMD May Be Reversed by Experimental Drug
“Wet” AMD accounts for only 20% of all AMD cases but causes almost 90% of the associated vision loss. Dr. Mark Johnson is conducting clinical trials of rhuFabV2 for patients with early AMD.
Summer 2003 - Vitamin A: It’s the Survival Factor for Sight
The retina’s master cell layer, the retinal pigment epithelium (RPE), regulates and nourishes our photoreceptors. Dr. Debra Thompson has found that Vitamin A plays a crucial role in these functions. She discovered RPE65, the gene that regulates Vitamin A in the eye.
Spring 2003 - Kellogg Tests New Device for Patients with Vexing Cornea Problems
Imagine the disappointment of having a corneal transplant fail – not just once but repeatedly. Dr. Shahzad Mian is testing a plastic implant that has brought 20/20 vision to some of these patients who would otherwise be blind.